I took a starter position this morning. Chart looks nice, private placements, and best of all the message boards aren't filled with idiots yet!
I agree with many posters that there must be something going on in the background that we aren't aware of – the stock has been too strong for it not to. My question is more along the lines of the technicals. Is anyone else not concerned about how overbought this seems to be? The stock seems ripe for a decent pullback. Sure, we've had some intraday pullbacks (yesterday for example) but I'm talking about a healthy pullback to pull the RSI down.
They definitely have a media communication problem and that's been my beef as a long for the past two years. Too much time goes by without updates on any trial progress. The only time the company communicates with shareholders is at quarterly cc's and those are normally the same, quarter over quarter. I used to be very bullish and very long until I got stopped out on the Thursday before they announced results, which were done in a very poor manner. Fool me once shame on you (UC), fool me twice shame on me and I wasn't about to be fooled again. The sharp move from $3+ to low $2's were a sign that something wasn't right and to get out. Even after all of this, after the dust has settled a bit, the company still hasn't updated investors on anything.
I'm personally not going to sit in this stock awaiting updates, hoping their positive. The company has fumbled too many times for me to trust them.
I'm in Canada with TD Waterhouse and my account shows that I have PZG shares but when I click on the name, it tells me that there are no matches found for the symbol. I still don't have any CDE shares in my account.
Exactly what I'm waiting for. Where would you put your buy target?
The shorts aren't bothersome, it's easy to ignore them. The share price tumbling is what's hard to ignore.
Piper Jaffray says Athersys will present Phase II MultiStem data at the European Stroke Organization Conference on Sunday. The study has a high bar for success and is more likely to miss the primary composite endpoint, Piper states. The stock could potentially trade as low 45c, the company's cash position, on such an event, Piper believes. However, if the study shows statistical significance on the primary endpoint, the firm thinks shares will trade "meaningfully higher" as MultiStem would be the first new stroke therapy in 20 years. Piper says it would be a buyer of Athersys even if the study misses the primary composite endpoint but hits on secondary endpoint of NIHSS. The firm keeps an Overweight rating on Athersys with a $4 price target.
lol... as someone who is in both ATHX and CYTR, I get a kick out of this post.